Reply to: "Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed"

Hepatol Int. 2024 Oct;18(5):1589-1590. doi: 10.1007/s12072-024-10682-6. Epub 2024 Jul 8.
No abstract available

Keywords: Conversion therapy; Hepatocellular carcinoma; Overall survival; Prognostic model; Progression-free survival.

Publication types

  • Letter

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / therapy
  • Chemoembolization, Therapeutic* / methods
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / therapy
  • Phenylurea Compounds* / therapeutic use
  • Prognosis
  • Quinolines* / therapeutic use

Substances

  • lenvatinib
  • Phenylurea Compounds
  • Quinolines
  • Immune Checkpoint Inhibitors